← Leaderboards
Andrew B Mahon
Nanometics, Llc
$2,030,376
Attributed
$2,030,376
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $865.4K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,030,376 · 2
By mechanism
R44$1,730,700 · 1
R43$299,676 · 1
Top collaborators
No co-investigators on record.
Most similar at Nanometics, Llc
Same institution · by research overlap
- Steven Isaacman$10,967,667
- Eric K Rowinksy$999,624
Others in their field
Other Emerging Leaders on “Technological Innovation”
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Mark Marino · Venturewell$58,366,489
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Neeta Jain · Vignet, Inc.$37,355,117
- Scott Andrew Sutherland · Vignet, Inc.$37,355,117
- Mark Begale · Vignet, Inc.$37,355,117
Research focus
Technological InnovationCommercial ApplicationLeadCessation Of LifeInvestigational New Drug ApplicationDesignDoseIn VitroSmall Business Innovation Research GrantUnited StatesScreeningPreventCostHealthcare SystemsBenchmarkingActinic KeratosisCompliance BehaviorCommercializationCorneal OpacityCreamCell Mediated Immune ResponseClinical DevelopmentAftercareAnti-Tumor Immune Response
Grant awards (3)
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.$865,339
R44 · FY2023 · AR · contact PI
Investigational new drug enabling studies for the development of a topical fixed dose combination drug product to treat actinic keratosis and prevent cutaneous squamous cell carcinoma.$865,361
R44 · FY2022 · AR · contact PI
A novel small molecule Bax activator as an oral therapeutic for the treatment of lung cancer.$299,676
R43 · FY2019 · CA · contact PI